Product Description
Our first target indication will be acute myeloid leukemia (AML). AML is one of the most common and lethal hematopoietic malignancies. So far, the current treatment for AML is still insufficient and there is a significant unmet medical need for high-risk naïve patients and relapse refractory patients. The expression of m6A modifying proteins is upregulated in AML cells; Depletion of the m6A writer proteins, induces the differentiation and apoptosis of myeloid leukemia cells and delays the occurrence of leukemia in mice. Inhibition of m6A reader protein in AML, eradicates cancer cells and leukemic stem cells (LSC) without compromise normal hematopoiesis. (Sourced from: https://www.futurx.co.il/portfolio/catchme/)
Mechanisms of Action: m6A Depletor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CatchMe Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Acute Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|